Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, investigators plan to test two potential mechanisms contributing to diastolic dysfunction among asymptomatic persons with HIV who are on cART. The first proposed mechanism is that heightened systemic immune activation/inflammation in HIV contributes to myocardial inflammation, which in turn promotes myocardial fibrosis. The second mechanism is that ectopic fat deposition (increased visceral adiposity) in HIV relates to increased intramyocardial lipid content, which in turn contributes to diastolic dysfunction. Both HIV positive and HIV-negative participants will undergo cardiac MRI/ MRS imaging studies for evaluation of myocardial fibrosis, myocardial inflammation, and intramyocardial lipid content. Traditional markers of CVD risk, inflammatory markers/immune, hormonal markers, and markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS outcomes. Additionally, a small subset of participants with HIV will undergo longitudinal evaluations to assess effects of a clinically prescribed hormonal therapy on myocardial structure and function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterizing HIV-related Diastolic Dysfunction

NCT02860156

Heart Failure HIV Diastolic Dysfunction

COMPLETED

Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: a Cardiac MRI Study

NCT03238755

HIV Infections

ACTIVE_NOT_RECRUITING

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160

Human Immunodeficiency Virus Lipodystrophy Cardiac Disease

COMPLETED

Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology

NCT01089114

HIV Cardiovascular Disease

COMPLETED

Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up

NCT01196273

Coronary Heart Disease Heart Failure HIV +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Diastolic Dysfunction Myocardial Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-positive

Cardiac MRI/MRS

Intervention Type OTHER

HIV-negative

Cardiac MRI/MRS

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac MRI/MRS

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥40 and ≤75 years
* documented HIV infection
* participant report that combination antiretroviral therapy (cART) (any regimen) has been taken stably without \> 4 week interruption for at least 180 days prior to study entry (report of switching regimens in that time frame is permissible)

• age ≥40 and ≤75 years

Exclusion Criteria

* CD4 \< 100 cell/mm3
* current active AIDS-defining illness
* current active or recent (not fully resolved within 30 days prior to study entry) systemic bacterial, fungal, parasitic, or viral infections (except HIV, HBV, human papillomavirus \[HPV\], or HCV)
* current active cancer
* clinical ASCVD, as defined by 2013 ACC/AHA guidelines (including previous diagnosis of AMI, ACS, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, PAD), by subject report
* clinical diagnosis of HFpEF or HFrEF, by subject report
* diagnosed DM on antihyperglycemic medication
* current, active use of immune suppressant medication including oral or intravenous corticosteroid or injectable biologic (oral ASA or NSAID use permitted)
* eGFR \<45 ml/min/1.73 m2 calculated by CDK-EPI
* standard contraindications to MRI procedure based on MGH MRI Patient Procedure Screening Form - including history of severe allergy to gadolinium
* use of lipid lowering agents including statin drugs, fibrates, ezetimibe, red yeast rice, niacin or omega-3 fatty acids (\>3 grams/day in standalone formulations) in the 90 days prior to study entry
* use of ACE inhibitor, ARB, or aldosterone receptor blocker in the 90 days prior to study entry
* pregnancy or breastfeeding (female subjects of reproductive potential)
* other medical, psychiatric, or psychological condition that, in the opinion of the study investigator, would interfere with completion of study procedures

HIV negative subjects:

* HIV infection
* current active or recent (not fully resolved within 30 days prior to study entry) systemic bacterial, fungal, parasitic, or viral infections (except HIV, HBV, human papillomavirus \[HPV\], or HCV)
* current active cancer
* clinical ASCVD, as defined by 2013 ACC/AHA guidelines (including previous diagnosis of AMI, ACS, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, PAD), by subject report
* clinical diagnosis of HFpEF or HFrEF, by subject report
* diagnosed DM on antihyperglycemic medication
* current, active use of immune suppressant medication including oral or intravenous corticosteroid or injectable biologic (oral ASA or NSAID use permitted)
* eGFR \<45 ml/min/1.73 m2 calculated by CDK-EPI
* standard contraindications to MRI procedure based on MGH MRI Patient Procedure Screening Form - including history of severe allergy to gadolinium
* use of lipid lowering agents including statin drugs, fibrates, ezetimibe, red yeast rice, niacin or omega-3 fatty acids (\>3 grams/day in standalone formulations) in the 90 days prior to study entry
* use of ACE inhibitor, ARB, or aldosterone receptor blocker in the 90 days prior to study entry
* pregnancy or breastfeeding (female subjects of reproductive potential)
* other medical, psychiatric, or psychological condition that, in the opinion of the study investigator, would interfere with completion of study procedures

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes